월드와이드
북미
유럽
미국
덴마크
프랑스
독일
이탈리아
네덜란드
폴란드
스웨덴
스위스
영국
중남미
아시아 태평양
아르헨티나
브라질
멕시코
호주
인도
말레이시아
뉴질랜드
태국
싱가포르
제품을 제조하여 판매하거나, 구매하여 소비하는 모든 사람들이 제품에 대해 어떻게 느끼는지를 반영하는 전체적인 집단 의식인 제품 의식구조에 대해 자세히 알아봅시다.
자세히
UL Advantage는 UL 인증의 입증된 장점에 대해 더욱 빠르고 스마트하며 유연한 경로를 제공하는 안전 인증에 대한 혁신적인 접근법입니다.
자세히
안전하고 적합한 제품을 세계 시장에 판매할 수 있도록 지원합니다.
자세히
계속해서 증가하고 있는 지속 가능성 영역에 대해 광범위한 서비스를 제공합니다.
자세히
웰빙(well-being)에 필수적인 중요 시스템에 UL의 기술, 안전 및 성능 전문성을 활용합니다.
자세히
세계적인 공급망에서 요구되는 제품 시험과 평가 서비스를 제공합니다.
자세히
교육, 자문 서비스 및 통찰력있는 리더십을 통해 기업에 경쟁력을 제공해 드립니다.
자세히
Share

Biocompatibility testing for global regulatory submissions

UL offers the health sciences industries a way to complete another required submission through one provider. UL's biocompatibility test services meet the requirements of the specifications generally accepted by the three major global medical device markets: ISO 10993, USP, or MHLW. Working with UL for biocompatibility testing provides the benefit of test plan consolidation, which can be faster than managing multiple test labs.

Biocompatibility is defined as "compatibility with living tissue or a living system by not being toxic, injurious, or physiologically reactive and not causing immunological rejection." For medical devices, which come into contact with the human body for the purpose of treatment, diagnosis, or physical aid, making sure that every point of contact will not cause irritation, changes in blood composition, or toxic response is especially critical. Even if a material that makes up the medical device has been tested for biocompatibility, processes such as manufacturing, shipping, packaging, and sterilization may have adverse affects on the material's composition and how it reacts in different environments. Because of these potential changes, biocompatibility is an important test protocol that must be completed for every medical device end product prior to receiving global regulatory approvals.

Simultaneous testing

The three global major medical device markets prescribe different test protocols to assess biocompatibility in medical devices. The U.S. FDA and European Union commonly accept the ISO 10993 standards for biocompatibility. USP (U.S. Pharmacopoeia) standards are accepted by the U.S. FDA, are generally regarded as more stringent, and may be used by manufacturers as a marketing tool or for specific uses. Finally, Japan's MHLW has test criteria different from both the ISO 10993 and USP protocols. Through UL's family member, mdt medical device testing, GmbH (MDT), we offer our customers a comprehensive test package to satisfy requirements for global regulatory approvals, and use the "worst case" criteria to minimize testing, samples required, and time.

The UL advantage

  • Custom project planning -- Our staff will work with you to prepare a project plan to meet your current and future product launch needs. This includes meeting with senior-level scientists with years of experience in preparing test protocols to meet regulatory submission requirements.
  • Experience -- Through MDT, a UL company you gain access to over 50 years of experience in analytical chemistry, biocompatibility, toxicology, bioanalytical, microbiological, pharmacology testing, and specialty services.
  • Global accreditation services -- UL is a leader at getting our customers access to existing and emerging markets so you only need to work with one test, regulatory and certification provider to meet your global sales and distribution needs.

Additional resources